Phase 3 ECHO: Safety Data Review

Opinion
Video

Medical experts analyze and provide insights on safety findings from the Phase 3 ECHO trial, offering their professional interpretations of the data.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 9th 2025
Article
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
September 9th 2025
Podcast
The safety profile of sonrotoclax was generally well-tolerated, and emergent toxicities were manageable in patients with mantle cell lymphoma.

Sonrotoclax Meets Primary ORR End Point in Mantle Cell Lymphoma

Roman Fabbricatore
September 9th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 9th 2025
Podcast
Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Considerations for CAR T Use Across Large B-Cell Lymphoma Variants

Roman Fabbricatore
September 9th 2025
Article
Pre-planned interim results from the phase 3 EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

SC Epcoritamab Combo Meets ORR/PFS End Points in R/R Follicular Lymphoma

Tim Cortese
September 9th 2025
Article